Navigation Links
Joslin Diabetes Center and DiabetesSeriesLive to Present Four-Part CME Series on the Advances of Insulin Replacement Therapy

Joslin Diabetes Center, in partnership with DiabetesSeriesLive, will present a series of live-online CME programs on the evolution of insulin replacement therapy, focusing on new perspectives, evolving technologies, and clinical applications. This educational series is available to clinicians at no cost.

Recent, exciting advances in both the development of pharmacologic tools and technical devices aimed at replicating the normal secretion of insulin in people with diabetes have brought us considerably closer to ideally mimicking natural insulin secretory patterns. However, for these new advances to be optimally utilized, clinicians must be familiar with their indications, usage parameters, and approaches to troubleshooting should the need arise.

“We are excited to present this four-part series of educational programs from the leaders in the space to keep clinicians up to date on the newer insulins and devices,” said Robert Rosenbloom, President and CEO of PlatformQ Health. “It is our hope that the education clinicians access on DiabetesSeriesLive will stimulate learners to think about what they can and should do in their own office setting versus outsource to regional specialty centers, making quality care available to a larger number of patients with diabetes.”

The first one-hour program will air live online Thursday, September 14, 2017 from 3:00-4:00pm ET on Richard S. Beaser, MD and Alissa R Segal, PharmD will present Insulin Options for Diabetes: Update on the Evolution. This free online CME session will identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations, discuss the clinical importance of similarities and differences between a biosimilar insulin and a reference insulin, and describe key, clinically relevant data derived from pivotal trials of new and emerging insulin products. Dr. Beaser is Associate Professor of Medicine at Harvard Medical School and Senior Physician & Medical Director of CME at Joslin Diabetes Center. Dr. Segal is Professor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences (MCPHS) University and Clinical Pharmacist and Diabetes Educator at Joslin Diabetes Center.

Participants will be able to submit questions for the panel prior to and during the live broadcast, to be addressed in real time by the speakers. To submit a question prior to the program, please click here.

“The significant advances in the insulin replacement therapies that are now becoming available empower clinicians caring for people with diabetes to better replicate natural insulin action patterns, but in so doing, challenge those clinicians to learn to take full advantage of these new tools,” shared Dr. Richard Beaser. “Clinicians would therefore benefit from practical, expert-led education in order to understand the full spectrum of insulin replacement therapies which will insure that all of their patients who need these treatment options can have them available in a timely and effective manner. I’m thrilled to help present this series of programs on DiabetesSeriesLive to help arm them to do that.”

The following three additional programs will follow this autumn on, expanding on new breakthroughs in insulin therapies:

Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options will air live Thursday October, 29, 2017 1:00-2:00pm ET. Topics discussed will include recognizing the indications for advancement to insulin replacement therapy for people with Type 2 Diabetes and applying the important pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations to clinical care. Dr Richard Beaser will be joined by Dr. Richard E. Pratley, the Samuel E. Crockett Chair in Diabetes Research; Director at Florida Hospital Diabetes Institute and Adjunct Professor at Sanford Burnham Presbys Medical Discovery Institute.

Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider will air live Thursday, November 30, 2017 12-1pm. Dr. Richard Beaser will be joined by Dr. Anne L. Peters and Dr. Jeremy H Pettus. Dr. Peters is Director, Clinical Diabetes Program and Professor, Keck School of Medicine at University of Southern California. Dr. Pettus is Assistant Professor of Medicine, Division of Endocrinology at University of California, San Diego.

Dr. Beaser, Dr. Peters and Dr. Pettus will remain for a second program at 1pm ET, titled The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options. This will air live Thursday, November 30, 2017 1-2pm.

The first of these two programs will explore methods to utilize currently available insulins to more accurately replicate natural insulin secretory patterns. In the second program, the use of new devices will be discussed, including insulin pumps and glucose monitoring devices. Practical information will be provided for non-specialist clinicians to help them avail their patients of these tools when indicated.

Each program will be available online on for 6 months after its live date for 1.0 AMA PRA Category 1 Credit(s)™, totaling 4.0 CME/ CE credits available for this series. Clinicians can register for the series on DiabetesSeriesLive.

This series is presented by Joslin Diabetes Center in joint providership with PlatformQ Health Education and are supported by educational grants from Novo Nordisk Inc. and Medtronic, Inc.

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcomes-centric education aimed at improving patient care. The company's unique education platform allows participants to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S. For more information, visit or follow @joslindiabetes.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related medicine news :

1. Joslin Diabetes Center, Affiliate at Raritan Bay Medical Center Celebrates Opening of New Office in Old Bridge
2. In Joslin trial, Asian Americans lower insulin resistance on traditional diet
3. Joslin scientists identify process that affects fat distribution and metabolic syndrome
4. DiabetesSisters Welcomes Program Manager to Oversee Social Media Engagement
5. DrugDev Invites Pharmaceutical Companies to Support “George’s RunforType1” 100km (62 miles) on 30 September in London to End Type 1 Diabetes in Children
6. Retina Group of New York to Provide Diabetic Retinopathy Education at Tour de Cure and Step Out Walk to Stop Diabetes Fundraiser
7. Fruit Street Becomes the First Digital Health Company to Deliver the CDC’s Diabetes Prevention Program via Live Group Telehealth Classes
8. VDEX Diabetes Releases White Paper on Afrezza and Recommends New Treatment Protocol For Type 1 and Type 2 Diabetes.
9. ZyDoc Chairman James M. Maisel, MD Presents “Using NLP to Identify and Manage Patient Populations at Risk for Diabetes and Complications” at 5th World Diabetes Congress
10. ZyDoc Chairman James M. Maisel, MD Chairs the Epidemiology and Prevention of Diabetes Section at the 5th World Congress of Diabetes 2017 in Prague, Czech Republic
11. Team Type 1 Foundation Announces Over 100 Scholarships to Collegiate Athletes with Diabetes
Post Your Comments:
(Date:5/16/2020)... , ... May 15, 2020 , ... For patients who have gone to see ... that the office has always had in place. After being allowed to re-open during the ... that patients and staff are as safe and comfortable as possible while going through their ...
(Date:5/15/2020)... ... May 15, 2020 , ... Collagen has taken the ... natural channel alone in 2019, according to a 2020 Nutritional Outlook ‘Ingredients to Watch’ ... further and further away from the high molecular weight, low-impact products of the past ...
(Date:5/15/2020)... PHOENIX (PRWEB) , ... May 15, 2020 , ... How ... question remains unanswered. Thousands of private practice offices are not set up to see ... lack of patient and disease history are challenging to overcome. Doctors and patients need ...
(Date:5/14/2020)... ... May 13, 2020 , ... The Long Island-based ... Developmental Disabilities. , The vision of the Center for Developmental Disabilities is to ... values are embraced: Everyone is treated with dignity and respect. Individual strengths and ...
(Date:5/11/2020)... ... May 11, 2020 , ... PathologyWatch announced today a $5M ... Capital with additional funding by individual investors. PathologyWatch is emerging as the ... process while reducing costs to clinics and enhancing patient care. , ...
Breaking Medicine News(10 mins):
(Date:5/16/2020)... FREEDOM, Pa. (PRWEB) , ... May 16, 2020 , ... ... has developed a low-cost proning cushion to help patients lay face down for extended ... providing proning devices for over 15 years to PTs and Pain Management professionals. We ...
(Date:5/14/2020)... ... May 14, 2020 , ... A new study from the National Alliance ... United States increased by 9.5 million from 2015 to 2020 and now encompasses more ... family caregivers are in worse health compared to five years ago. As the demand ...
(Date:5/14/2020)... ... ... Clear Labs , providers of the only automated and intelligent diagnostic ... by Redmile Group, as well as existing investors including Wing VC, Menlo Ventures, Tyson ... raised $62M. , In addition to supporting ongoing commercialization of the company’s food ...
Breaking Medicine Technology: